Lilly Doubles Down on Nimbus in $1.3B Oral Obesity Pact
Nimbus Therapeutics has entered into a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to
Read moreNimbus Therapeutics has entered into a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to
Read moreStriatech is pleased to announce its next Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision, which will be held on
Read moreBeonchip has introduced the next generation of Microfluidic chips! Simplified Organ-on-Chip Technology for In Vitro Research and Drug Discovery Discover
Read moreZentriForce Pharma offers advanced Micro Differential Scanning Calorimetry (μ-DSC) services – a highly sensitive and label-free technique for studying thermally
Read moreZentriForce Pharma provides an integrated suite of nanoparticle analysis services, offering advanced characterisation for biotherapeutics, gene therapy vectors, and lipid-based
Read moreZentriForce Pharma Research provides comprehensive analytical support for gene therapy product development, combining hydrodynamic and orthogonal techniques to characterise complex
Read moreZentriForce Pharma provides Dynamic Light Scattering (DLS) services for rapid and sensitive particle size, aggregation, and stability analysis in biopharmaceuticals,
Read moreZentriForce Pharma provides specialised analytical services through Size Exclusion Chromatography coupled with Multi-Angle Light Scattering (SEC-MALS) – a gold-standard technique
Read moreZentriForce Pharma Research, a contract research organisation (CRO) with deep expertise in hydrodynamic orthogonal analytical methods, offers a full suite
Read moreZentriForce Pharma provides analytical services for oligonucleotide characterisation, supporting the development of antisense oligonucleotides, siRNA, mRNA and related modalities. Ensuring
Read more